Lupus & antiphospholipid syndrome
Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
Authors' conclusion
Disease-related and VUS features, in addition to SCORE, may help to improve LLT decision making in SLE. GCCVH and aPLpos improve LLT eligibility similarly and to a greater degree than PDD or LLDASno.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) without prior cardiovascular events, diabetes or APS
- Participants
- 210 patients
- Exposure
- Systematic Coronary Risk Evaluation (SCORE) alone and SCORE plus vascular US or disease-related risk enhancers vs SCORE+carotid and femoral ultrasound (cfUS) for lipid-lowering therapy (LLT) eligibility
- Outcome
- Eligibility for LLT per European Society of Cardiology (ESC) guidelines according to SCORE, with and without vascular US and disease-related features
Methodological detailsSCORE plus cfUS as reference modality for LLT eligibility, phi coefficient and Cohen's kappa
- SCORE plus cfUS as reference modality for LLT eligibility
- Phi coefficient and Cohen's kappa
Main finding
As reported in the abstract
LLT eligibility
LLT eligibility
SCORE+cfUS
Observational data: associations, not effects.
Further findings
Atherosclerotic plaques detected
| Outcome | Low-risk | Moderate-risk |
|---|---|---|
| Classification ability (phi) of SCORE risk enhancers | ||
| SCORE+PDD phi | 0.06 | 0.13 |
| GCCVH (cut-off ≥11 g) phi | 0.23 | 0.20 |
| LLDASno phi | 0.07 | 0.16 |
| aPLpos in aPLpos/APT- phi | 0.06 | 0.33 |
Agreement (kappa) with SCORE+cfUS for LLT eligibility
- SCORE+GCCVH and SCORE+aPLpos at least fair agreement in low-risk or moderate-risk and in aPLpos/APT- moderate-risk patients, respectively
- kappa ≥0.20
- Better for SCORE+prolonged disease duration (PDD) in moderate-risk patients and for SCORE+carotid ultrasound (cUS) in both groups
Original publication
Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations. RMD Open. Published 9 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →